RESUMO
Activities of crude extract of Cryptolepis Sanguinolen and Crateva Adansonii leaves and their interactions were evaluated.Crude methanol extracts of Crateva adansonii and Cryptolepis sanguinolenta leaves were obtained by cold maceration. Antimicrobial activities of the extracts were carried out against six bacteria ie Pseudomonas aeruginosa, Escherichia coli, Salmonella typhii, Staphylococcus aureus, Klebsiella pneumoniae, Bacillus subtilis and two fungi which includes Aspergillus niger and Candida albicans using agar dilution method MICs of methanol extract of Crateva adansonii against the six bacteria are Pseudomonas aeruginosa -12.5 mg/ml, Escherichia coli - 6.25 mg ml, Salmonella typhi - 12.5 mg/ml, Staphylococcus aureus - 2.5 mg/ml, Klebsiella pneumonia - 6.25 mg/ml, Bacillus subtilis - 12.5 mg/ml, fungi Aspergillus niger - 12.5 mg/ml, Candida albicans - 12.5 mg/ml. While the MICs of methanol extract of Cryptolepis sanguinolenta against the six bacteria. Pseudomonas aeruginosa - 12.5 mg/ml, Escherichia coli - 6.25 mg ml, Salmonella typhii - 12.5 mg/ml, Staphylococcus aureus - 12.5 mg/ml, Klebsiella pneumoni - 12.5 mg/ml. Bacillus subtilis - 6.25 mg/ml and for fungi Aspergillus niger - 12.5 mg/ml, Candida albicans - 6.25 mg/ml. Combined activity of the two plant extracts against Escherichia coil, klebsiella pneumoniae, Bacillus subtilis and Candida albicans was carried out at the ratios of 1:1, 2:1 and 1:2 of extracts of Crateva adansonii and Cryptolepis sanguinolenta respectively. Combination 1:2 and 2:1 were found to be effective and able to inhibit Escherichia coli and Candida albicans. The result of this work shows that the extracts of Cryptolepis sanguinolenta and Cranteva Adansonii have both antifungal and antibacterial effects and their combination is effective in some bacterial and fungal infection most especially Candida albicans infection.
RESUMO
OBJECTIVE@#To formulate and evaluate in vitro, surface-modified solid lipid microspheres containing halofantrine using lipid matrix formed from goat fat and a phospholipid (P90H).@*METHODS@#The model drug, halofantrine in an increasing concentration of 1%, 2%, 3%, 4% and 5% w/w was incorporated into surface-modified solid lipid microspheres formulated by hot homogenization. Effect of drug concentration on the encapsulation efficiency was studied. The dispersion was evaluated using particle size, particle morphology, pH and encapsulation efficiency. The drug formulation with highest encapsulation efficiency was selected and used for the release studies and compared with the release from a commercial dosage form (Halfan® 250 mg tablet, Glaxo-Smithkline, Mayenne France) using simulated gastric fluid (SGF pH 1.2), simulated intestinal fluid (SIF pH 7.2) and phosphate buffer (pH 6.8) as biorelevant media. Results were analyzed statistically and the level of significance was taken to be P < 0.05).@*RESULTS@#Discrete and spherical solid lipid microspheres were produced. The particle size of the dispersion was low (32.48-33.87 μm) with minimal particle growth and high encapsulation efficiencies (86.8%-91.0%) after 3 months. The pH of the microspheres dispersion changed appreciably after 3 months. In vitro release result obtained revealed sustained and controlled drug release from the lipid microspheres compared with the tablet dosage form.@*CONCLUSIONS@#Formulation of halofantrine as solid lipid microspheres presents a better alternative to the conventional tablet formulation as the in vitro dissolution of the highly lipophilic halofantrine was highly improved.